MENA Oncology Conference

22nd and 23rd October 2010, Cairo, Egypt 

"Fleming Gulf's MENA Oncology Conference has been organized as a result of the rising incidence of breast cancer in the MENA (Middle-Ease and North-African) region, and seeks to bring this disease to the forefront of public awareness and discussion. Breast cancer, despite all medical and technological advances, has been on the rise in the last 50 years or so and is expected to be diagnosed in 25 million women over the next 25 years, with incidence rates climbing in developing countries. In many parts of the world outside of the U.S. and Western Europe, awareness of the disease remains low, ultimately resulting in higher mortality rates.

2^nd Annual Pharmaceutical Risk-Sharing & Value-Based Pricing & Reimbursement Models

14th-15th September, 2010
Washington DC, USA

There is clearly an increasing need for more innovative pricing and reimbursement agreements to help to balance the often conflicting objectives of pharmaceutical and medical technology manufacturers, payers, health plans, health technology assessment (HTA) & physicians and patients. The industry faces a sustained increase in the cost of healthcare and an ever-increase in the range of expensive drugs and technologies available as potential therapies. In light of this, difficult choices need to be made by payers and HTAs about which products receive funding from increasingly restricted healthcare budgets, especially with often insufficient clinical and real-life evidence available.

2^nd Annual Pharmaceutical Market & Patient Access for Chronic Disease Therapies

15th-16th September, 2010
Brussels, Belgium

Chronic diseases are taking a steadily increasing share of national health spending in the developed world, especially due to an ageing population and unhealthy lifestyles. Such conditions and treatments do not often seem as controversial and as high on the political, healthcare system and media‘s agenda, when compared to the very expensive cancer or orphan drugs, for example. Typically, drugs for chronic diseases are priced at very reasonable levels, yet are making a large budget impact, effecting significant percentages of the entire population.  

Evolution Summit 2010

27-29 October 2010, Fairmont Le Montreux Palace, Montreux, Switzerland

6th Annual

Pharma Marketing & Branding Excellence

25th - 26th January 2011., Milan, Italy

Following five successful annuals, Jacob Fleming Group invites you to the 6th Annual Pharma Marketing & Branding Excellence. Yet again we have gathered worldwide Pharma marketing specialists who will share their knowledge with you. Hear them speak about the most powerful marketing strategies and network face-to-face.  Come and listen to real life case studies, discover innovative approaches and benefit from interactive discussions with your peers to benchmark your experiences.

6th Annual

Project & Portfolio Management in the Pharmaceutical Industry

28th - 29th September 2010, Milan, Italy

What is the road to develop a strong portfolio to add value to key stakeholders?
How to deal with the risk in project & portfolio management to ensure optimal performance? This event will bring together the experts from the pharmaceutical industry to benchmark their best practices to enhance the innovation & create value in a current payer-driven and limited resources environment

2^nd Successful eCTD Lifecycle Management

Prague, September 14th and 15th, 2010

Pharma IQ is delighted to announce the 2nd Successful eCTD Lifecycle Management conference, being held in Prague on the 14th and 15th of September 2010. With eCTD submissions taken a firm hold in the US and Japan, they are now making their mark in Europe. Now eCTD submissions are becoming the preferred format for regulatory submissions in Europe so it is essential that you are equipped with in-house expertise and external solutions to ensure first time compliance and submission success!

3rd Annual Drug Repositioning & R&D Enhancement

September 16-17, 2010
Philadelphia, PA, USA

This conference will showcase more than 15 industry perspectives on the most effective scientific and strategic approaches to extend life-cycle management of drug products. Marcus Evans invites senior level executives from pharmaceutical, biotech, and medical device companies to take this opportunity to benchmark best practices with their industry peers in order to develop sound strategies for drug repositioning.